Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Stepped up their Corporate Presentation Game

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon Oct 30, 2020 10:31am

111 Views

Post# 31812562

RE:Stepped up their Corporate Presentation Game

They really hit home the Q4 submissions for NASH and Cancer. With only a month left in the Fiscal year they must be feeling good about the submission or they would not have pressed the point so hard. That is exciting news for us as we should hear news in the next 60-90 days. One thing is for sure, year end financials are now due by the end of January (as per SEC rules), so we can be fairly confident on some news and Q&A within 90 days.

<< Previous

Bullboard Posts

Next >>

Mid-year review: How has gold been performing?